z-logo
Premium
Green tea consumption reduced the athergenic properties on the high LA or DHA diets induced oxidizability status in apo E KO mice.
Author(s) -
Lee Myoungsook,
Park Soojin,
Oh Hyunhee,
Park Miyoung,
Kim Hyosook,
Kim Maeha,
Jang Soojeong,
Kim Kkochbyul
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.a1123-d
Epidemiological studies have indicated that regular consumption of red wine and green tea is associated with a reduced risk of coronary heart disease. This study have examined whether green tea have antiangiogenic properties in atherogenic in vivo model, apo E KO mice, after high PUFA intake increased high LPO metabolites such as 4‐HNE and MDA. Apo E KO mice were fed either LA or DHA (20 %) with or without 5% green tea in diet for 8 weeks. Plasma lipid profiles and markers of in vivo lipid peroxidation(Ox‐LDL and 8‐OH‐DG), oxidizability and FFA composition in liver, apoptotic signaling changes in heart tissue were measured and compared to the wild type or apo E(−/−) control. Both of LA and DHA increased lipid profiles, LPO, Ox‐LDL and 8‐OH‐DG in plasma and liver, respectively and aortic lesion formation. Green tea consumption tended to reduce the primary causal mechanism of atherogenic phenomena such as oxidizability in both of LA or DHA treated atherogenic mice. As the results of changes on apoptotic signaling in heart, stress induced apoptotic signaling proteins such as caspase3, cytochrome c release and NFκB were increased, but bcl‐2 protein was decreased by high PUFA diet. However, green tea remarkably reduced the expression of the apoptotic signaling. Therefore, the potentialities of the green tea as antiatherosclerotic properties of dietary antioxidants were tested in this study and will be more discussed. [The funds were given by KOSEF & Ministry of Health & Welfare (02‐PJI‐PG3‐22004‐019)]

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here